Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Vertex Says Benefits of Hepatitis C Drug Candidate Lasts to 24 Weeks

By Pharmaceutical Processing | August 10, 2010

CAMBRIDGE, Mass. (AP) — Vertex Pharmaceuticals Inc. said today that a study showed extended treatment with its hepatitis C drug candidate telaprevir led to better results for some patients.

Vertex said patients who responded quickly to treatment with telaprevir had better results after 24 weeks of therapy than after 12. However it said there was no benefit to extending therapy to 48 weeks.

The company said 92 percent of patients who responded well to telaprevir had had undetectable levels of the hepatitis C virus after 24 weeks of treatment. After 48 weeks, 88 percent of patients had undetectable virus levels. Patients were chosen to receive extended treatment if their virus levels was undetectable after 4 weeks and 12 weeks of treatment in an earlier study.

The company plans to file for Food and Drug Administration approval of telaprevir in the fourth quarter. The drug is seen as a potential billion-seller for Vertex.

The clinical trial was called ILLUMINATE, and it was a follow up to a previous study called ADVANCE. Patients who were responded well to treatment with telaprevir were then enrolled in the longer ILLUMINATE study, and their treatment was extended to 24 or 48 weeks. Patients who did not have a quick response to telaprevir were given standard hepatitis C drugs.

The most common side effects of telaprevir treatment were fatigue, itching, nausea, anemia, rash, and headache. Vertex said most of those side effects were mild or moderate.

 

Related Articles Read More >

Wyzo
Wyzo high-speed pick-and-place sidebot wins design awards
Purdue University
Purdue University launches institute for advanced manufacturing of pharmaceuticals
Sanofi logo
Sanofi introduces its first digital accelerator 
Cambridge Pharma launches with UK plant in Cambridge Research Park

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards